For patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic variants, the OlympiA trial demonstrated improved invasive disease-free survival through treatment with the adjuvant PARP inhibitor olaparib [48], recently becoming a part of clinical treatment guidelines [9]. This evidence concerns the gene BRCA1 and breast cancer.